vendredi 4 janvier 2013

Focus : Which are the antibodies to watch in 2013?





The start of the New Year signals that it is time for mAbs’ annual review of the therapeutic monoclonal antibodies  (mAbs) in active Phase 2/3 or Phase 3 clinical studies.  the entire clinical pipeline currently includes ~350 mAbs, but most of these are in early development. As of the beginning of 2013, our “Antibodies to watch” list includes 28 single mAbs and one mAb mixture that are undergoing evaluation in Phase 3 studies for inflammatory or immunological disorders, cancers, high cholesterol, osteoporosis, Alzheimer disease and infectious disease. in alphabetical order, the  28 mabs are alirocumab, AMG 145, elotuzumab, epratuzumab, farletuzumab, gantenerumab, gevokizumab, inotuzumab, ozogamicin, itolizumab, ixekizumab, lebrikizumab, mepolizumab, naptumomab estafenatox, necitumumab, nivolumab,  obinutuzumab, ocrelizumab, onartuzumab, racotumomab, ramucirumab, reslizumab, romosozumab, sarilumab, secukinumab, sirukumab, solanezumab, tabalumab, and vedolizumab. the mixture of actoxumab and bezlotoxumab is being evaluated in two Phase 3 studies as a treatment for Clostridium difficile infection.


INN or code name

Molecular type
Target(s)
Current
phase

Phase 2/3 or 3 indications





Naptumomab estafenatox
(ABR-217620)

Murine Fab immunotoxin

Trophoblast glycoprotein, also known as TPBG or 5T4
Phase 2/3
Renal cell carcinoma
Ramucirumab

Human IgG1
VEGFr2
Phase 3
Gastric; liver, breast, colorectal,
NSCL cancers
Farletuzumab
Humanized IgG1
Folate receptor α
Phase 3
Ovarian cancer
Obinutuzumab

Humanized IgG1
CD20
Phase 3
diffuse large B cell lymphoma,
CLL, NHL
Elotuzumab
Humanized IgG1
CD2
Phase 3
Multiple myeloma
Inotuzumab
ozogamicin

Humanized IgG4

AdC
CD22
Phase 3
ALL; NHL
Necitumumab
Human igG1
EGFr
Phase 3
NSCL cancer
Onartuzumab

Humanized IgG1
Fab-Fc

cMet
Phase 3
NSCL cancer; gastric cancer
Racotumomab
Murine
GM3
Phase 3
NSCL cancer





Therapeutic antibodies in Phase 2/3 or Phase 3 clinical studies of cancer indications. Table compiled from information available as of November 15, 2012. ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; NHL, nonHodgkin lymphoma; VEGFr2, vascular endothelial growth factor receptor 2, NSCL, non-small-cell lung.


Source: Which are the antibodies to watch in 2013? Janice M. Reichert. mAbs 5:1, 1–4; January/February 2013
Free paper available at:

Aucun commentaire:

Enregistrer un commentaire

Enregistrer un commentaire